In fact, there is a clear difference in disease activity and joint destruction between ACPA-positive and ACPA-negative RA, and there is a growing belief in the treatment field that biologics should be used more aggressively in the former [26]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.